Loading clinical trials...
Loading clinical trials...
To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT07011147 · Type 1 Diabetes (T1D), Type 2 Diabetes, and more
NCT00357890 · Diabetes Mellitus, Insulin-Dependent
NCT04591925 · Diabetes Mellitus, Type I, IDDM, and more
NCT01781975 · Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, and more
NCT01338922 · Diabetes Mellitus, Insulin-Dependent
Columbia University
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions